Beclomethasone (generic), Vanceril, QVAR

Beclomethasone (generic), Vanceril, QVAR Newswire

Comprehensive Real-Time News Feed for Beclomethasone (generic), Vanceril, QVAR.

Results 1 - 20 of 38 in Beclomethasone (generic), Vanceril, QVAR

  1. New Report Available: PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023Read the original story

    Friday Oct 17 | PR-inside.com

    Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists , inhaled corticosteroids , inhaled corticosteroids and long-acting beta-agonists , and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years.

    Comment?

  2. Research and Markets: GSK's Flovent (Asthma) - Forecast and Market Analysis to 2023Read the original story w/Photo

    Wednesday Oct 15 | Business Wire

    Originally approved by the Food and Drug Administration in 1996, GSK's Flovent is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in children and adults.

    Comment?

  3. Research and Markets: Chiesi's Fostair (Asthma) Outlook - Forecast and Market Analysis to 2023Read the original story

    Wednesday Oct 15 | Business Wire

    Fostair, developed by Chiesi, is an FDC of the ICS beclomethasone dipropionate and the LABA formoterol fumarate. Beclomethasone dipropionate is a prodrug that is metabolized to two active metabolites.

    Comment?

  4. Research and Markets: Advair (Asthma) by GSK - Forecast and Market Analysis to 2023Read the original story

    Tuesday Oct 14 | Business Wire

    Advair is an FDC of fluticasone propionate and salmeterol xinafoate developed by GSK. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity.

    Comment?

  5. Research and Markets: SkyePharma's Flutiform (Asthma) - Forecast and Market Analysis to 2023Read the original story

    Tuesday Oct 14 | Business Wire

    The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists , inhaled corticosteroids , inhaled corticosteroids and long-acting beta-agonists , and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years.

    Comment?

  6. A dry powder formulation inhaler offers protection from pneumoniaRead the original story w/Photo

    Friday Oct 10 | Examiner.com

    Pneumonia is a leading cause of morbidity and mortality. The Agency for Science, Technology and Research reported on Oct. 8, 2014 a dry powder inhaler formulation offers very good protection against pneumonia-causing bacteria.

    Comment?

  7. Double blast to ward off pneumonia: Dry powder inhaler formulationRead the original story w/Photo

    Wednesday Oct 8 | Science Daily

    A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteria, scientists report. Community-acquired pneumonia, a type of lung inflammation contracted outside of a hospital or nursing-home setting, is most often caused by infections with bacteria, such as Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus.

    Comment?

  8. Teva: Overlooked And Potentially UndervaluedRead the original story w/Photo

    Thursday Oct 9 | Seeking Alpha

    Growth has been tepid for Teva, in response they have streamlined operations and have continued to increase R&D spend into core growth areas. Teva offers an attractive 2 to 1 reward to risk profile even in the midst of potential major competition versus their key drug Copaxone.

    Comment?

  9. A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteriaRead the original story w/Photo

    Wednesday Oct 8 | PhysOrg Weblog

    Despite advances in vaccination and antimicrobial therapy, community-acquired pneumonia remains a leading cause of morbidity and mortality, even in highly developed countries. Desmond Heng, Reginald Tan and co-workers at the A*STAR Institute of Chemical and Engineering Sciences have now developed a dry powder inhalation formulation to treat bacterial infections associated with this disease.

    Comment?

  10. 11 Charts That Should Make People Really Embarrassed About The US Healthcare SystemRead the original story w/Photo

    Tuesday Sep 23 | Silicon Alley Insider

    We spend more on healthcare than any other developed nation, yet we lead far shorter lives. A baby born on American soil is the most expensive in the world, yet our newborns have a lower chance of surviving past infancy than those born in eight other developed nations.

    Comment?

  11. Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical DevelopmentRead the original story

    Tuesday Sep 23 | Sys-Con Media

    Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development in the areas of formulation research, analytical method development, quality control , and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including PrevnarA , TetramuneTM, HibTITERA , MeningitecA Conjugate and meningitis B Lipoprotein Subunit Vaccines.

    Comment?

  12. Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in...Read the original story w/Photo

    Sunday Sep 21 | PRWeb

    LifeScienceIndustryResearch.com adds "Flovent - Forecast and Market Analysis to 2023" to its store. Obtain sales forecast for Flovent from 2013-2023 in top eight countries .

    Comment?

  13. Rx Product NewsRead the original story

    Sep 10, 2014 | Pharmacy Times

    QVAR Marketed by: Teva Respiratory, LLC Indication: The FDA has approved QVAR for the maintenance treatment of asthma as prophylactic therapy in patients 5 years and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, when adding QVAR may reduce or eliminate the need for systemic corticosteroids.

    Comment?

  14. The negative effects of cortisolRead the original story

    Sep 9, 2014 | Castanet.net

    Cortisol is a hormone that is absolutely crucial for life. Without it we would not be able to survive.

    Comment?

  15. Health Buzz: Watch: Deaf Baby Hears for the First TimeRead the original story

    Sep 5, 2014 | US News & World Report

    This type of video always gets to us. Tony and Michelle Lever's 7-week-old baby, Lachlan, was born with moderate to severe sensorineural hearing impairment in both ears, a condition that left him deaf and unlikely to develop speech without any intervention.

    Comment?

  16. What's New in Asthma Management?Read the original story w/Photo

    Sep 4, 2014 | US News & World Report

    For some people with extremely severe asthma, using an inhaler and taking several medications is all part of the daily routine. It was a muggy 2011 Fourth of July in Illinois, and Kenny Beyer, 33, a severe asthmatic, opted for some exercise indoors.

    Comment?

  17. Inhaled medications: Nefarious reasons for the lack of competitionRead the original story w/Photo

    Aug 29, 2014 | Kevin, M.D.

    Check out the prices for nebulizer solutions of albuterol and budesonide . They are totally affordable.

    Comment?

  18. Soligenix Receives Additional Niaid Funding to Advance Development of OrbeShield(TM) in Gi ArsRead the original story

    Aug 1, 2014 | Freshnews

    Soligenix, Inc. , a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to ... (more)

    Comment?

  19. Asthma inhalers may suppress children's growthRead the original story w/Photo

    Jul 17, 2014 | Medical News

    Corticosteroid drugs that are given by inhalers to children with asthma may suppress their growth, evidence suggests.

    Comment?

  20. Asthma inhalers may stunt children's growth, study findsRead the original story w/Photo

    Jul 17, 2014 | National Post

    Adults who were prescribed common asthma inhalers while growing up are likely to be shorter than they might have been.

    Comment?